Trial Profile
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs OPT 821 (Primary) ; Ovarian cancer vaccine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Proof of concept; Therapeutic Use
- 22 Oct 2019 Results published in the Gynecologic Oncology
- 07 Aug 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results assessing efficacy presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.